About Us
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries.
Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with ten patent holders for thirteen HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals and a tuberculosis treatment. MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC).
Featured
Discover MedsPaL
MedsPaL, MPP’s medicines patents and licences database, is a free resource that provides information on the intellectual property status of selected patented essential medicines in low- and middle-income countries.
MPP in Numbers
patent holders with MPP signed agreements
generic manufacturers and product developers have sublicences from MPP
countries have benefitted from access to MPP-licensed products
ongoing pharmaceutical development projects
Billion dollars saved by the international community, from January 2012 to December 2020
Billion doses of treatment supplied from January 2012 to December 2020
Million patient-years of treatment through MPP’s generic partners, from January 2012 to December 2020
For Everyone Everywhere
Discover where we helped and what we have achieved
Patent and licensing status: last updated on 30 November 2020 (see announcement). Disclaimer | Product availability data from MPP sublicensees: last updated in March 2021 (data as of 31 December 2020) | Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions
Impact Stories
How access to antiretrovirals is building the future
Key Publications
Annual Reports
06 October 2020
Twitter Feed
ViiV Healthcare @ViiVHC
We’re proud of our partnerships with @ViatrisInc @MacleodsPharm @MedsPatentPool @CHAI_health @UNITAID aimed at providing access to age-appropriate treatment for a younger population in #LMICs to help to close the gap between #HIV treatment options available for adults & children https://t.co/KzkLnOlGTG
Nelson J. Otwoma @NJotwoma
My activities yesterday included facilitating virtual interaction between #SallyAgallo & @MedsPatentPool on #NCDs especially Cancer and HIV and the challenges with diagnostics and treatment @NEPHAKKENYA @MOH_Kenya @NCDAK @ncdalliance @kenconetwork @cancer_kenya @cancerinstitute https://t.co/1P0SNS1YTb
MedicinesPatentPool @MedsPatentPool
💪Excited to report that MPP generic manufacturing partners are starting to supply #LMICs with @WHO-recommended #paediatric #ARV formulation. Read our statement👉 https://t.co/tay0MkUBwW #BetterDrugs4Kids #UHC #Access2Meds #GlobalHealth #HIV @ViatrisInc @MacleodsPharm @ViiVHC https://t.co/aZmbNPzjTJ
MedicinesPatentPool @MedsPatentPool
🙌Welcome to @GAP_f_Network, the Global Accelerator for Paediatric Formulations Network, on Twitter! >GAP-f is a @WHO-hosted network created to respond to the paediatric treatment gap. More👉https://t.co/3wOl04bGxb @Penta_ID @CHAI_health @EGPAF @MedsPatentPool #BetterDrugs4Kids